Cogentix Medical Inc

Cogentix Medical — Proxy Contest (May 2016)

29 slides from Cogentix Medical's proxy contest presentation, May 3, 2016

  1. Slide 1: Cogentix Medical Inc. (CGNT) Investor Presentation - Lewis C. Pell

    Cogentix Medical Inc. (CGNT) Investor Presentation - Lewis C. Pell May 3, 2016 Exhibit 1

  2. Slide 2: Company Overview

    Company Overview Formed in 2015, following the merger of Uroplasty (UPI) and Vision-Sciences (VSCI). Company provides proprietary, innovative technologies to specialty markets including urology, gynecology, bariatric medicine, critical care, gastroenterology, otolaryngology, and pulmonology. Product

  3. Slide 3: Time Line

    Time Line March 2015: Shareholders approved UPI and VSCI merger. Pursuant to the merger transaction, UPI management led by Robert C. Kill, assumed charge of the combined entity – Cogentix Medical (“CGNT”). The post-merger board comprised of 8 members: 5 from UPI and 3 from VSCI. February 2016: Lewis

  4. Slide 4: Why Change is Needed?

    Why Change is Needed? Destruction of shareholder value Rob Kill (CEO) and former UPI directors (“UPI Directors”), who now serve on CGNT board, have a history of destroying shareholder value. UPI’s share price fell 48% during Rob’s tenure as its CEO prior to the merger close Moreover, CGNT’s share pr

  5. Slide 5: Why Change is Needed? – contd.

    Why Change is Needed? – contd. Misaligned Executive Compensation UPI Directors have failed to align executive compensation with performance. They continue to reward Mr. Kill for sup-bar performance and sustained destruction of shareholder value. In 2014, ISS recommended AGAINST the Say on Pay (SOP)

  6. Slide 6: Total Shareholder Return & Operational Performance

    Total Shareholder Return & Operational Performance

  7. Slide 7: UPI's TSR significantly underperformed its peers during Mr. Kill's tenure as CEO

    UPI’s TSR significantly underperformed its peers during Mr. Kill’s tenure as the CEO UPI’s performance under Mr. Kill as the CEO Source: Factset. See Appendix for TSR peer group

  8. Slide 8: CGNT has also underperformed its peers under Mr. Kill and UPI Directors

    CGNT has also underperformed its peers under Mr. Kill and UPI Directors CGNT’s performance under Mr. Kill Source: Factset. See Appendix for TSR peer group

  9. Slide 9: Failure to Fulfil Merger-Related Promises

    Failure to Fulfil Merger-Related Promises Source: Uroplasty investor presentation dated 12/22/2014 http://www.sec.gov/Archives/edgar/data/890846/000114036114046116/form425.htm, Reality Failed. CGNT removed revenue guidance for 2016 Failed. Public filings/website do not show any new product Failed. L

  10. Slide 10: Failure to Fulfil Merger-Related Promises (contd.)

    Failure to Fulfil Merger-Related Promises (contd.) Source: Uroplasty/Vision Sciences investor presentation dated 12/22/2014 http://www.sec.gov/Archives/edgar/data/890846/000114036114046116/form425.htm, The Medtronic competitive pressure was already known at the time of merger What new products are p

  11. Slide 11: Failure to Address Competitive Threat

    Failure to Address Competitive Threat “we [CGNT] expect the formal launch of a competitive PTNS technology from a large established medical device manufacturer later this month. As a result, we think it is possible this launch will cause some short term competitive disruption for Urgent PC. .....How

  12. Slide 12: Lack of Product Innovation

    Lack of Product Innovation Roth Investor Conference, March 2015 Roth Investor Conference, March 2016

  13. Slide 13: Disappointing Outlook for CGNT

    Disappointing Outlook for CGNT Shareholders have serious concerns about CGNT’s strategic plan due to: Lack of visibility for its largest revenue contributor – Urgent PC High cash burn rate Rising debt level Increasing interest expense 1QCY14 2QCY14 3QCY14 4QCY14 9mths 1QCY15 2QCY15 3QCY15 4QCY15 9mt

  14. Slide 14: Performance Summary

    Performance Summary Declining share price No new product launch/announcement Deteriorating cash position Negative growth rates for three product lines Uncertain outlook for the largest product – Urgent PC What is the Strategic Plan to create value? Why should investors believe in it?

  15. Slide 15: Corporate Governance Concerns

    Corporate Governance Concerns

  16. Slide 16: Questionable choice of compensation peer group

    We question UPI Directors choice of peer group considering CGNT is much smaller than the peers Inappropriate Compensation Peer Group Source: Factset, SEC filings. * CGNT Revenue for 9 months ended 31 Dec. 2015

  17. Slide 17: Mr. Kill's Pay Is Excessive

    Despite significantly lower revenue than its comp. peers, Mr. Kill has one of the highest salary and bonus Mr. Kill’s Pay Is Excessive Source: Factset, SEC Filings. * CGNT: Assuming $50mn revenue for FY15. Total Salary + Bonus = Guaranteed salary of $500,000 + actual bonus for transition period $367

  18. Slide 18: High CEO Comp. Despite Deteriorating Performance

    Mr. Kill seems to have benefited from high comp. despite massive losses High CEO Comp. Despite Deteriorating Perf. Source: Factset, SEC Filings. Net Income adjusted for merger related costs

  19. Slide 19: UPI Directors have a history of not aligning pay with performance

    UPI Directors’ have a history of not aligning pay with performance At the 2013 shareholder meeting , 39% of votes cast were AGAINST the Say on Pay proposal. ISS also AGAINST the executive compensation package. At the 2014 shareholder meeting, ISS again recommended AGAINST the Say on Pay proposal. Th

  20. Slide 20: ISS Recommendation: Uroplasty 2014 Meeting

    ISS Recommendation: Uroplasty 2014 Meeting “COMPENSATION COMMITTEE COMMUNICATION AND RESPONSIVENESS At the 2013 annual meeting, the company's say-on-pay received 61.1 percent shareholder support. Last year, ISS issued an adverse recommendation because the company entered into a new employment agreem

  21. Slide 21: Departure of Key Executives and Directors

    Departure of Key Executives and Directors Several key employees and board members have either resigned/decided not to stand for re-election) since the merger. The list includes: Sven A. Wehrwein: Audit Committee Chair James P. Stauner: Lead Director and member of the Audit Committee Brett Reynolds:

  22. Slide 22: Our Plan

    Our Plan Our Plan: Corporate Governance Seek 3 seats on an a 7 member board – i.e. minority board representation. On March 28, 2016, prior to the Company’s prelim. proxy statement, Mr. Pell submitted a notice to nominate directors which included several proposals aimed at breaking lose Mr. Kill’s co

  23. Slide 23: Our Nominees: Lewis Pell

    Our Nominees: Lewis Pell Lewis C. Pell Lewis C. Pell is a co-founder of the Company and prior to the Merger, had served as the Chairman of the Board of the Company since 2005 until March 31, 2015. Mr. Pell is a founder or co-founder and chairman and director of several privately held medical device

  24. Slide 24: Our Nominees: Howard Zauberman

    Our Nominees: Howard Zauberman Howard I. Zauberman Served as a director of the Company since November 2013 and was the Interim Chief Executive Officer of the Company in May 2013. Prior to the Merger, Mr. Zauberman had also served as President and Chief Executive Officer of the Company. Has over 30 y

  25. Slide 25: Our Nominees: James A. D'Orta

    Our Nominees: James A. D’Orta James A. D’Orta Dr. James A. D’Orta currently serves on the board of directors of MedStar Health, Inc. Most recently served as a director and Chief Executive Officer of ACell, a Maryland-based medical device manufacturer from 2013-2015. Prior to becoming Chief Executive

  26. Slide 26: Appendix: Peer Groups

    Appendix: Peer Groups Compensation Peers* TSR peers** TickerName CUTR-USCutera, Inc. IRIX-USIRIDEX Corporation LMAT-USLeMaitre Vascular, Inc. STAA-USSTAAR Surgical Company SRDX-USSurModics, Inc. ATRC-USAtriCure, Inc. CYNO-USCynosure, Inc. Class A ETRM-USEnteroMedics Inc. RMTI-USRockwell Medical, Inc

  27. Slide 27: Why are we proposing nominees

    Why are we proposing 3 nominees- TO BE DECIDED There are 3 Class I seats up for re-election at the annual meeting. As such, we are nominating 2 incumbent directors (Howard and Lou) and are adding an independent nominee James D’Orta in light of the fact that one incumbent director has decided not to

  28. Slide 28: Additional Information

    Additional Information 28 Lewis C. Pell filed a definitive proxy statement, as amended, and an accompanying proxy card with the Securities and Exchange Commission on May 2, 2016 to be used to solicit proxies in connection with the 2016 Annual Meeting of Stockholders (including any adjournments or po

  29. Slide 29: Cautionary Statement Regarding Forward-Looking Statements

    Cautionary Statement Regarding Forward-Looking Statements 29 The information herein contains “forward-looking statements.” Specific forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and include, without limitation, words such as

Cogentix Medical — Proxy Contest (May 2016) on 6ix